FMNL3

Across TCGA pan-cancer cohorts, FMNL3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of FMNL3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where FMNL3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FMNL3 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where FMNL3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FMNL3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.629	<.001	9	view →
HNSC	All	IV	+0.693	<.001	8	view →
LSCC	Female	All	−0.559	<.001	8	view →
COAD	All	III,IV	+0.325	<.001	8	view →
CCRCC	All	All	+0.239	<.001	8	view →
PDAC	Female	All	+0.599	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

FMNL3–LUAD

Open the LUAD breakdown →